Pathophysiology  ||| S:0 E:16 ||| NNP
of  ||| S:16 E:19 ||| IN
rosacea ||| S:19 E:26 ||| NNS
:  ||| S:26 E:28 ||| :
redness ||| S:28 E:35 ||| CD
,  ||| S:35 E:37 ||| ,
telangiectasia ||| S:37 E:51 ||| NN
,  ||| S:51 E:53 ||| ,
and  ||| S:53 E:57 ||| CC
rosacea  ||| S:57 E:65 ||| VBG
The  ||| S:65 E:69 ||| DT
pathophysiology  ||| S:69 E:85 ||| NN
of  ||| S:85 E:88 ||| IN
rosacea  ||| S:88 E:96 ||| NN
involves  ||| S:96 E:105 ||| VBZ
a  ||| S:105 E:107 ||| DT
large  ||| S:107 E:113 ||| JJ
number  ||| S:113 E:120 ||| NN
of  ||| S:120 E:123 ||| IN
factors  ||| S:123 E:131 ||| NNS
that  ||| S:131 E:136 ||| WDT
are  ||| S:136 E:140 ||| VBP
at  ||| S:140 E:143 ||| IN
times  ||| S:143 E:149 ||| NNS
difficult  ||| S:149 E:159 ||| JJ
to  ||| S:159 E:162 ||| TO
correlate ||| S:162 E:171 ||| VB
.  ||| S:171 E:173 ||| .
There  ||| S:173 E:179 ||| EX
is  ||| S:179 E:182 ||| VBZ
not  ||| S:182 E:186 ||| RB
a  ||| S:186 E:188 ||| DT
single  ||| S:188 E:195 ||| JJ
physiopathological  ||| S:195 E:214 ||| JJ
model ||| S:214 E:219 ||| NN
.  ||| S:219 E:221 ||| .
Nevertheless ||| S:221 E:233 ||| RB
,  ||| S:233 E:235 ||| ,
today  ||| S:235 E:241 ||| NN
it  ||| S:241 E:244 ||| PRP
seems  ||| S:244 E:250 ||| VBZ
to  ||| S:250 E:253 ||| TO
have  ||| S:253 E:258 ||| VB
been  ||| S:258 E:263 ||| VBN
established  ||| S:263 E:275 ||| VBN
that  ||| S:275 E:280 ||| IN
two  ||| S:280 E:284 ||| CD
essential  ||| S:284 E:294 ||| JJ
factors  ||| S:294 E:302 ||| NNS
are  ||| S:302 E:306 ||| VBP
involved ||| S:306 E:314 ||| VBN
:  ||| S:314 E:316 ||| :
vascular  ||| S:316 E:325 ||| NNS
and  ||| S:325 E:329 ||| CC
inflammatory ||| S:329 E:341 ||| JJ
.  ||| S:341 E:343 ||| .
The  ||| S:343 E:347 ||| DT
disease  ||| S:347 E:355 ||| NN
occurs  ||| S:355 E:362 ||| VBZ
in  ||| S:362 E:365 ||| IN
individuals  ||| S:365 E:377 ||| NNS
with  ||| S:377 E:382 ||| IN
a  ||| S:382 E:384 ||| DT
predisposition ||| S:384 E:398 ||| NN
,  ||| S:398 E:400 ||| ,
mainly  ||| S:400 E:407 ||| RB
a  ||| S:407 E:409 ||| DT
light  ||| S:409 E:415 ||| JJ
phototype  ||| S:415 E:425 ||| NNS
subjected  ||| S:425 E:435 ||| VBN
to  ||| S:435 E:438 ||| TO
substantial  ||| S:438 E:450 ||| JJ
variations  ||| S:450 E:461 ||| NNS
in  ||| S:461 E:464 ||| IN
climate ||| S:464 E:471 ||| NN
.  ||| S:471 E:473 ||| .
On  ||| S:473 E:476 ||| IN
a  ||| S:476 E:478 ||| DT
background  ||| S:478 E:489 ||| NN
of  ||| S:489 E:492 ||| IN
primary  ||| S:492 E:500 ||| JJ
vascular  ||| S:500 E:509 ||| JJ
anomaly ||| S:509 E:516 ||| NN
,  ||| S:516 E:518 ||| ,
external  ||| S:518 E:527 ||| JJ
factors  ||| S:527 E:535 ||| NNS
( ||| S:535 E:536 ||| -LRB-
climate ||| S:536 E:543 ||| NN
,  ||| S:543 E:545 ||| ,
exposure  ||| S:545 E:554 ||| NN
to  ||| S:554 E:557 ||| TO
ultraviolet  ||| S:557 E:569 ||| VB
rays ||| S:569 E:573 ||| NNS
,  ||| S:573 E:575 ||| ,
cutaneous  ||| S:575 E:585 ||| JJ
flora ||| S:585 E:590 ||| NNS
,  ||| S:590 E:592 ||| ,
etc. ||| S:592 E:596 ||| FW
)  ||| S:596 E:598 ||| -RRB-
contribute  ||| S:598 E:609 ||| VBP
to  ||| S:609 E:612 ||| TO
the  ||| S:612 E:616 ||| DT
development  ||| S:616 E:628 ||| NN
of  ||| S:628 E:631 ||| IN
abnormal  ||| S:631 E:640 ||| JJ
superficial  ||| S:640 E:652 ||| JJ
blood  ||| S:652 E:658 ||| NN
vessels ||| S:658 E:665 ||| NNS
,  ||| S:665 E:667 ||| ,
with  ||| S:667 E:672 ||| IN
a  ||| S:672 E:674 ||| DT
low  ||| S:674 E:678 ||| JJ
permeability ||| S:678 E:690 ||| NN
.  ||| S:690 E:692 ||| .
The  ||| S:692 E:696 ||| DT
edema  ||| S:696 E:702 ||| NN
that  ||| S:702 E:707 ||| IN
results  ||| S:707 E:715 ||| NNS
undoubtedly  ||| S:715 E:727 ||| RB
favors  ||| S:727 E:734 ||| VBZ
the  ||| S:734 E:738 ||| DT
colonization  ||| S:738 E:751 ||| NN
and  ||| S:751 E:755 ||| CC
multiplication  ||| S:755 E:770 ||| NN
of  ||| S:770 E:773 ||| IN
Demodex  ||| S:773 E:781 ||| NNP
folliculorum ||| S:781 E:793 ||| NN
.  ||| S:793 E:795 ||| .
This  ||| S:795 E:800 ||| DT
parasite  ||| S:800 E:809 ||| NN
creates  ||| S:809 E:817 ||| VBZ
inflammation ||| S:817 E:829 ||| VBN
,  ||| S:829 E:831 ||| ,
directly  ||| S:831 E:840 ||| RB
and  ||| S:840 E:844 ||| CC
indirectly ||| S:844 E:854 ||| RB
,  ||| S:854 E:856 ||| ,
which  ||| S:856 E:862 ||| WDT
is  ||| S:862 E:865 ||| VBZ
seen  ||| S:865 E:870 ||| VBN
in  ||| S:870 E:873 ||| IN
the  ||| S:873 E:877 ||| DT
papules  ||| S:877 E:885 ||| NN
and  ||| S:885 E:889 ||| CC
pustules  ||| S:889 E:898 ||| NN
as  ||| S:898 E:901 ||| IN
well  ||| S:901 E:906 ||| RB
as  ||| S:906 E:909 ||| IN
granulomas ||| S:909 E:919 ||| NN
.  ||| S:919 E:921 ||| .
Inflammation  ||| S:921 E:934 ||| NNP
from  ||| S:934 E:939 ||| IN
rosacea  ||| S:939 E:947 ||| NN
is  ||| S:947 E:950 ||| VBZ
also  ||| S:950 E:955 ||| RB
characterized  ||| S:955 E:969 ||| VBN
by  ||| S:969 E:972 ||| IN
innate  ||| S:972 E:979 ||| JJ
immune  ||| S:979 E:986 ||| JJ
system  ||| S:986 E:993 ||| NN
anomalies ||| S:993 E:1002 ||| NN
,  ||| S:1002 E:1004 ||| ,
with  ||| S:1004 E:1009 ||| IN
an  ||| S:1009 E:1012 ||| DT
increase  ||| S:1012 E:1021 ||| NN
in  ||| S:1021 E:1024 ||| IN
the  ||| S:1024 E:1028 ||| DT
expression  ||| S:1028 E:1039 ||| NN
of  ||| S:1039 E:1042 ||| IN
epidermal  ||| S:1042 E:1052 ||| JJ
proteases  ||| S:1052 E:1062 ||| NN
and  ||| S:1062 E:1066 ||| CC
production  ||| S:1066 E:1077 ||| NN
of  ||| S:1077 E:1080 ||| IN
pro-inflammatory  ||| S:1080 E:1097 ||| JJ
cathelicidin  ||| S:1097 E:1110 ||| JJ
peptides ||| S:1110 E:1118 ||| NN
.  ||| S:1118 E:1120 ||| .
In  ||| S:1120 E:1123 ||| IN
addition ||| S:1123 E:1131 ||| NN
,  ||| S:1131 E:1133 ||| ,
facial  ||| S:1133 E:1140 ||| JJ
hypersensitivity  ||| S:1140 E:1157 ||| NN
exists ||| S:1157 E:1163 ||| VBZ
,  ||| S:1163 E:1165 ||| ,
even  ||| S:1165 E:1170 ||| RB
though  ||| S:1170 E:1177 ||| IN
the  ||| S:1177 E:1181 ||| DT
cutaneous  ||| S:1181 E:1191 ||| JJ
barrier  ||| S:1191 E:1199 ||| NN
is  ||| S:1199 E:1202 ||| VBZ
not  ||| S:1202 E:1206 ||| RB
altered ||| S:1206 E:1213 ||| VBN
.  ||| S:1213 E:1215 ||| .
Finally ||| S:1215 E:1222 ||| RB
,  ||| S:1222 E:1224 ||| ,
rhinophyma  ||| S:1224 E:1235 ||| NN
remains  ||| S:1235 E:1243 ||| VBZ
poorly  ||| S:1243 E:1250 ||| RB
explained ||| S:1250 E:1259 ||| VBD
;  ||| S:1259 E:1261 ||| :
the  ||| S:1261 E:1265 ||| DT
vascular  ||| S:1265 E:1274 ||| JJ
abnormalities  ||| S:1274 E:1288 ||| NNS
induce  ||| S:1288 E:1295 ||| VB
local  ||| S:1295 E:1301 ||| JJ
production  ||| S:1301 E:1312 ||| NN
of  ||| S:1312 E:1315 ||| IN
transforming  ||| S:1315 E:1328 ||| VBG
growth  ||| S:1328 E:1335 ||| NN
factor  ||| S:1335 E:1342 ||| NN
β1  ||| S:1342 E:1345 ||| NNP
( ||| S:1345 E:1346 ||| -LRB-
TGF-β1 ||| S:1346 E:1352 ||| NNP
)  ||| S:1352 E:1354 ||| -RRB-
capable  ||| S:1354 E:1362 ||| JJ
of  ||| S:1362 E:1365 ||| IN
creating  ||| S:1365 E:1374 ||| VBG
fibrosis  ||| S:1374 E:1383 ||| NNS
and  ||| S:1383 E:1387 ||| CC
therefore  ||| S:1387 E:1397 ||| RB
cutaneous  ||| S:1397 E:1407 ||| JJ
thickening ||| S:1407 E:1417 ||| NN
.  ||| S:1417 E:1419 ||| .
